Skip to main content
BGI Genomics Co., Ltd. logo

BGI Genomics Co., Ltd. — Investor Relations & Filings

Ticker · 300676 ISIN · CNE100003449 Shenzhen Stock Exchange Professional, scientific and technical activities
Open in API
Filings indexed 1,656 across all filing types
Latest filing 2019-08-12 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300676

About BGI Genomics Co., Ltd.

https://www.bgi.com

BGI Genomics Co., Ltd. is a leading provider of integrated solutions for precision medicine, specializing in genomic sequencing and proteomic services. The company offers a comprehensive portfolio of clinical diagnostics and research services across various fields, including reproductive health, oncology, and infectious diseases. Key products include non-invasive prenatal testing, hereditary cancer screening, and pathogen identification tools. Leveraging proprietary DNBseq sequencing technology, BGI Genomics provides high-throughput, cost-effective genomic data analysis to healthcare providers, research institutions, and pharmaceutical companies worldwide. The organization focuses on advancing personalized medicine through large-scale genomic research and the development of innovative diagnostic applications, aiming to improve health outcomes by making advanced genetic insights accessible to a global population.

Recent filings

Filing Released Lang Actions
关于青岛华大基因健康医疗产业园投资进展暨全资子公司完成工商注册登记的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding the progress of an investment project and the completion of the business registration of a wholly-owned subsidiary. It details the investment decision, the establishment of a subsidiary, and the registration details including business license information. The document is short (1357 characters) and does not contain financial statements or detailed financial analysis. It is an announcement about corporate investment and subsidiary registration, not a financial report or detailed management report. It fits best under Regulatory Filings (RNS) as a general regulatory announcement about corporate activities that do not fit other specific categories.
2019-08-12 Chinese
关于持股5%以上股东拟以持有的本公司股份参与认购基金份额暨减持计划预披露公告
Major Shareholding Notification Classification · 95% confidence The document is a public announcement by Shenzhen BGI Genomics Co., Ltd. regarding a shareholder holding more than 5% of shares planning to reduce their holdings by subscribing to fund shares and a related share reduction plan. It details the shareholder's identity, the number of shares involved, the timing and method of the reduction, and compliance with relevant regulations. The document does not contain financial statements or detailed financial performance data but is a disclosure about a major shareholder's transaction and intentions related to shareholding and fund subscription. This fits the definition of a Major Shareholding Notification (MRQ), which covers notifications of changes in significant share ownership levels or related plans. The document length is 3276 characters, which is consistent with an announcement rather than a full report. Therefore, the appropriate classification is MRQ with high confidence.
2019-08-05 Chinese
关于参与投资设立产业投资基金的进展公告
Capital/Financing Update Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding the progress of their participation in establishing an industrial investment fund. It details the board meeting approval, fund registration, capital contributions, and regulatory filings related to the fund. The document is relatively short (2115 characters) and serves as a progress update and disclosure notice rather than a full financial report or detailed financial statements. It does not contain financial results, earnings data, or management discussion of financial performance. It is not a report itself but an announcement of investment and regulatory progress. Therefore, it fits best into the category of Capital/Financing Update (CAP), which covers updates on company fundraising and financing activities.
2019-07-18 Chinese
2019年半年度业绩预告
Earnings Release Classification · 95% confidence The document is titled '2019年半年度业绩预告' which translates to '2019 Half-Year Performance Forecast'. It provides estimated financial results for the period January 1, 2019 to June 30, 2019, including expected net profit and revenue growth. It explicitly states that the forecast is unaudited and that detailed financial data will be disclosed in the 2019 half-year report. The document is short (1110 characters) and serves as a performance forecast announcement rather than a full interim report containing actual financial statements or detailed analysis. Therefore, it is best classified as an Earnings Release (ER), which covers initial announcements of quarterly or periodical financial results with key highlights only. H1 2019
2019-07-12 Chinese
关于全资子公司中标河北省孕妇无创产前基因检测服务项目的公告
Regulatory Filings Classification · 95% confidence The document is an announcement from Shenzhen BGI Genomics Co., Ltd. regarding its wholly-owned subsidiary winning a bid for a prenatal gene testing service project in Hebei Province. It includes details about the project, the contracting parties, the budget, and the potential impact on the company. The document is relatively short (1279 characters) and does not contain any financial statements, quarterly or annual results, or detailed financial analysis. It is not a report but an announcement of a contract award. There is no indication of it being related to board changes, voting results, legal proceedings, or financing updates. Therefore, the document fits best into the category of a Regulatory Filing (RNS), which is a general regulatory announcement that does not fit into other specific categories.
2019-07-03 Chinese
关于控股股东部分股权解除质押的公告
Regulatory Filings Classification · 95% confidence The document is a public announcement regarding the release of a portion of pledged shares by the controlling shareholder of the company. It details the number of shares released from pledge, the dates involved, and the risk implications of the pledge. There is no financial statement, management discussion, or detailed report content. The document is short (1048 characters) and serves as a regulatory disclosure about share pledge status, which fits the category of a Regulatory Filing (RNS) rather than a financial report or capital update. It is not a Capital/Financing Update (CAP) because it does not discuss new financing or capital structure changes, only the release of pledged shares. Therefore, the best classification is Regulatory Filings (RNS).
2019-07-02 Chinese

Browse filings by year

10 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.